Systemic Sclerosis and Related Diseases

This study identifies dysfunctional type 1 immunity in SSc patients through altered T cell subsets and reduced IFN-γ production.

This paper identifies small molecules targeting the Tenascin C fibrinogen-like globe domain to reduce fibrosis in systemic sclerosis by inhibiting Toll-like receptor 4 signaling.

This study identifies NNMT as a key driver of fibroblast activation and skin fibrosis in systemic sclerosis by modulating TGFβ signaling and ECM production.

The paper demonstrates that anti-CD206 CAR T cells restore dermal white adipose tissue in systemic sclerosis by targeting CD206+ macrophages and reversing their effects on adipose-derived stem cells.

This study shows that the Wnt/lipogenesis axis mediates lipodystrophy and recovery in skin fibrosis by regulating lipid content and extracellular matrix.

This study shows bleomycin causes centromere damage and chromatin mislocalization in fibroblasts, linking it to systemic sclerosis features.

The paper identifies profibrotic monocyte-derived alveolar macrophages as a biomarker and therapeutic target in SSc-ILD by analyzing BAL fluid and lung explants.

The paper uses spatial transcriptomic methods to identify novel fibroblast subpopulations in systemic sclerosis skin and their pathogenic roles.

This study compares cAMP regulation and dedifferentiation in lung and skin myofibroblasts from scleroderma patients, finding tissue-specific differences in PGE2 response and p38 inhibition effects.

The paper maps the metabolic landscape of skin fibrosis in systemic sclerosis using single-cell analysis and identifies metabolically active cell types and their interactions.

This study uses Mendelian randomization to identify causal relationships between inflammation, metabolism, and systemic sclerosis, finding several risk and protective factors.

The paper examines metabolic profiles of circulating plasmacytoid dendritic cells (pDCs) in systemic sclerosis (SSc) patients, finding differences based on clinical phenotypes.

The paper identifies a CD57+ cytotoxic CD8 T cell subset expanded in SSc-ILD patients and links it to lung injury through CD155-CD226 interactions.

This study identifies a GPVI-platelet-neutrophil-NET axis that drives systemic sclerosis fibrosis and presents it as a therapeutic target.

The paper maps spatially-resolved transcriptomes in systemic sclerosis to identify a fibrotic niche and disease-specific cell states, linking them to clinical outcomes.

This study identifies SIX1 as a driver of dermal fibrosis in systemic sclerosis by linking its upregulation to adipocyte dysfunction and fibrotic gene expression.

This study shows RUNX1 is expressed in SSc fibroblasts and higher levels correlate with fibrosis severity, with hypomethylation and inhibitor effects supporting its role in fibrosis.

The paper characterizes single-cell transcriptomic and epigenomic features of a 3D skin-like model of systemic sclerosis, identifying fibroblast subpopulations and their interactions with macrophages.

This study shows CLIC4 regulates type 1 interferon signaling in SSc epithelial cells and inhibiting it blocks IFN pathway activation.

This study identifies aging and senescence signatures in SSc-ILD through gene expression analysis and telomere length measurement, linking them to disease pathology.

This study identifies ADRA2A as a major risk locus for Raynaud's syndrome through genome-wide association analysis and functional validation in vascular smooth muscle cells.

This study shows that reducing PKD2 activity in mice prevents bleomycin-induced dermal fibrosis by decreasing collagen and inflammatory markers.

The paper uses RNA-Seq to analyze SSc patient and control samples, identifying SPAG17 and SOX9 non-coding RNAs as novel factors in SSc pathogenesis.

This study identifies three monocyte transcriptional subgroups in SSc patients that correlate with disease activity, particularly lung function.

The paper identifies AREG as a critical driver of bleomycin-induced skin fibrosis and shows that targeting the AREG-EGFR-MEK pathway can prevent fibrosis.

The paper identifies differential DNA methylation in skin fibroblasts from African American systemic sclerosis patients, linking it to immune and metabolic pathways.

This study identifies a three-gene network influencing lung function and autoantibody status in systemic sclerosis patients through genetic interaction analysis.

The paper evaluates the antifibrotic effects of triple siRNA targeting SPARC, CCR2, and SMAD3 in a mouse model of fibrosis, showing reduced inflammation and fibrosis through multi-target intervention.

This paper uses machine learning to classify heart disease subgroups in systemic sclerosis using echocardiographic and skin transcriptome data, identifying distinct phenotypes and associated molecular pathways.

The paper performs a meta-analysis of gene expression data from SSc clinical trials to identify therapeutic targets and predict treatment response using machine learning.